Suggestions
Brenda Pote
Access Innovation Leader at Roche
Professional Background
Brenda Pote is a remarkably skilled Pricing and Market Access professional whose extensive experience covers over two decades in the Pharmaceutical Industry. Her career spans roles both in Australia and New Zealand, as well as internationally at Roche's esteemed Global Headquarters in Basel, Switzerland. Leveraging her deep understanding of Health Technology Assessment (HTA) and public reimbursement processes, Brenda consistently navigates complex challenges with poise and creativity. She has cultivated a proven track record on an international scale, intertwining her robust expertise with strong leadership skills to elevate her team's performance and deliver impactful solutions within the healthcare system.
Throughout her tenure at Roche, Brenda ascended through several key roles, including Access Innovation Leader, Associate Director of Market Access, and International Payer Strategy Leader. In these dynamic positions, she spearheaded initiatives that enabled the successful public reimbursement of Roche's innovative medicines, most notably for HER2+ metastatic breast cancer. Brenda's unwavering commitment to enhancing health outcomes for Australian patients reflects her passion for improving lives through effective healthcare interventions.
Brenda's ability to foster cross-functional collaboration is one of her defining attributes. She enthusiastically engages with various stakeholder groups, drawing on the collective expertise of her colleagues to create synergistic solutions for reimbursement challenges. This collaborative approach has not only bolstered her projects but has also enriched the professional development of her team members. Brenda finds immense satisfaction in coaching and mentoring aspiring professionals in her field, empowering them to achieve their individual potential.
Education and Achievements
Brenda's educational foundation is as impressive as her professional journey. She began her studies at St Clare's College, where she earned her High School Certificate, laying the groundwork for her future academic pursuits. Continuing her education at Monash University, Brenda achieved a Bachelor of Pharmacy (B.Pharm.), which equipped her with essential pharmaceutical knowledge and skills.
Further sharpening her expertise in pharmaceutical sciences, Brenda completed a Graduate Diploma in Drug Development & Pharmaceutical Sciences at Melbourne University. She also attended Sydney University for her Master's in Public Health, although this program remains incomplete. Her academic background aligns perfectly with her extensive work experience, providing her with the necessary insights to affect change within the sector.
Achievements
Brenda's career is marked by significant achievements, particularly in the realm of market access and health technology assessment. Her notable accomplishments include:
- Successful Reimbursement Initiatives: Brenda played a pivotal role in securing public reimbursement for Roche's HER2+ metastatic breast cancer medicines in Australia. This success is monumental, as these medications offer considerable health outcomes and support for those affected by breast cancer.
- Leadership in Market Access: As Access Innovation Leader and Associate Director Market Access at Roche, she led high-impact initiatives that shaped the strategic approach to market access in healthcare, contributing to Roche's reputation as a leader in innovative therapies.
- Mentorship and Team Development: Brenda delights in the growth of those around her, exemplifying her commitment to cultivating talent within the pharmaceutical sector. She embraces coaching, fostering future leaders and setting a standard for success in market access roles.
Brenda's enduring dedication to her profession, along with her collaborative spirit and strategic insights, continuously contributes to her field and the lives of countless patients. Her career reflects a profound commitment to healthcare advancement, mentorship, and the pursuit of excellence in pharmaceutical market access.
